Multi-Industrials

Looking into the Year Ahead

Andrew Obin

Research Analyst

BofAS

andrew.obin@bofa.com

+1 646 855 1817

David Ridley-Lane, CFA

Research Analyst

BofAS

david.ridleylane@bofa.com

+1 646 855 2907

Alexander Di Ruzza

Research Analyst

BofAS

alexander.di ruzza@bofa.com

+1 646 556 1811

Emily Shu

Research Analyst

BofAS

emily.shu@bofa.com

+1 646 556 2798



BofA Securities does and seeks to do business with issuers covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Refer to important disclosures on page 34-40. Price Objective Basis/Risk on page 27. Analyst Certification on page 32.

Top picks and themes for multi-industrials into 2021



- Top picks into 2021: ETN, PH, GE, CFX, EMR, and ROK
- Top themes into 2021:
 - 1. Still in the early stages of the cycle for multi-industrials
 - 2. Reshoring—automation, localization
 - 3. Conglomerates are back
 - 4. Oil & gas shifts focus to productivity
 - 5. 2021 non-res construction likely better than expected

Top picks into 2021: ETN, PH, GE, CFX, EMR, and ROK



ETN (\$155 PO): non-res and cyclical upside

Eaton is seeing improving demand, with 75% of its end markets up y/y by end of 3Q20. An expected cyclical recovery should benefit Eaton's aerospace segment (14% of 2020E EBIT) and short-cycle end markets. We view Eaton as a key beneficiary of re-shoring and President-elect Biden's clean energy spending platform. Stronger-than-expected non-residential construction recovery should benefit Eaton's electrical segments. As of 3Q-end, Eaton's Americas and Global electrical backlogs were up 11% and 7% respectively. ETN also has an improved and less cyclical portfolio mix post the divestiture of hydraulics, with roughly 80% of revenue tied to long-cycle electrical and aerospace. Eaton is on BofA's US 1 list, a collection of best investment ideas drawn from Buy-rated listed stocks.

PH (\$350 PO): multiple expansion & de-levering

We believe PH's performance through the downturn is a culmination of years of focus on operational improvement and capital allocation. Compared to prior cycles, PH's earnings and returns are now less cyclical than our coverage average despite its more cyclical end market exposure. PH's current trading multiple of 15x EV/EBITDA on CY21 is in line with multi-industrial peers, which we think bakes in EBITDA margins that are now more in line with multi-industrials. We think execution-driven multiple expansion is still a coming part of the story in 2021 as short-cycle end markets recover and aid in cyclical operating leverage. We also see a recovery in Aerospace as a vaccine is rolled out as a longer-term growth driver. Our DCF analysis indicates that PH (similar to CFX and GE) continues to be penalized relative to our coverage given its high leverage. PH has been working down leverage quickly and we see additional upside to valuation as the company de-levers through FY22.

GE (\$13 PO): FCF trajectory makes GE investible

GE shares and consensus 2021 Industrial FCF estimates both started to rise in October. We now forecast \$2.6bn in 2021E Industrial FCF, versus \$(1.0)bn in 2020E. We think GE has significant cushion in setting/meeting FCF expectations. Operationally, we forecast GE to have margin improvements across all segments. The pace of Aviation's revenue recovery remains uncertain, but profitability will rebound under a wide range of scenarios. This will be driven by the non-repeat of ~\$1.0bn in charges, carryover benefit from 2020 cost actions, and high incremental margins. In Healthcare, high-margin Pharmaceutical Diagnostics revenue should rise and backlog growth (+1% y/y organic in 3Q) supports low- to mid-single digit revenue growth. GE targets Gas Power margins to reach high single-digit range in 2021, versus our 3.2% 2020 estimate. Our current estimates are more conservative (5.2% in 2021E), but we see momentum on fixed cost reductions.

Top picks into 2021: ETN, PH, GE, CFX, EMR, and ROK



CFX (\$50 PO): cyclical upside, valuation attractive

Colfax is our top SMID cap pick. Cyclical recovery should be an uplift to FabTech (63% of 2020E revenue). We believe capital deployment could build the MedTech platform (37% of 2020E venue) to be a \$3bn+ business over time. With future acquisitions, we see Colfax's adjusted EBITDA doubling over the next five years, or growing at a 15% CAGR. MedTech's surgical segment has grown revenue at a double-digit pace over the last five years. DJO's shoulder, hips, and knees businesses have been rapidly gaining market share. Current valuation is attractive relative to both FabTech and MedTech peers.

EMR (\$95 PO): playing oil & gas efficiency

Emerson is arguably our most "contrarian" top pick. The consensus view is that the automation revenue recovery in oil & gas will take an extended period, given announced capex cuts by oil majors and still-weak demand. We are optimistic around oil & gas automation spending as we think oil & gas companies' capex budgets are likely to shift to productivity versus capacity expansion. We see EMR as the best positioned US player. This shift should act as a multiplier to the broader rebound in oil & gas capex. We think the company is well positioned with its improving mix of opex offerings (software, services, and efficiency upgrades like KOBX projects). Longer term, we see EMR becoming increasingly less reliant on capex-driven product sales to drive growth. More broadly, EMR also stands to benefit from the reshoring theme. The company is a key systems integrator for pharma and medical device companies and provides cold chain components critical to vaccine distribution. We see EMR's cost cutting plans (targeting \$175mn or 90-100bp of incremental cost savings) as adding additional momentum in FY21.

ROK (\$295 PO): automation pure play

We see ROK as the best way to play reshoring of US manufacturing. COVID-19's disruption of supply chains, along with tariffs and rising geopolitical tensions, are leading to a rebuilding of US manufacturing capacity. Firms are likely to focus on productivity to preserve margins, making automation players like ROK a key beneficiary. Rockwell has 7-8% share of the global industrial automation market, but a far greater share in the US (~60%). Ove the last fifteen years, ROK has grown at 2.2x industrial production. The BofA Economics team forecasts US IP to rebound in CY21. We see broader reshoring and more internal focus on software as adding momentum to ROK's recovery in FY21. We are optimistic on a cyclical recovery, supported by strong growth outlook in our Fluid Power Survey. See more on instances of reshoring manufacturing on page 8.

Thinking through the cycle for multis: economic cycle



MULTIS OUTPERFORMANCE CONTINUES 18-24 MONTH AFTER THE S&P 500 TROUGH




Source: BofA Global Research, Bloomberg

Note: Simple average of EMR, ETN, GE, HON, MMM, and PH share prices. Indexed to month of &&P500 trough

Thinking through the cycle for multis: PMI cycles



THE AVERAGE PMI TRAJECTORY OVER LAST EIGHT US RECOVERIES



Source: BofA Global Research, Bloomberg

Note: Measured from lowest PMI reading in an economic recession (Dec '08, Oct '01, Jan '02, No. '03, No. '75, N


'91, My '82, Jan '75, Nov '70, and May -60).

MULTIS AVERAGE OUTPERFORMANCE VS S&P 500 FOLLOWING THE FIRST PEAK IN PMI READINGS



Source: BofA Global Research, Bloomberg Note: Simple average of EMR, ETN, GE, HON, MMM, and PH share prices. Indexed to month of &&P500 trough

THE MESSY REALITY OF PMI – A VOLATILE ECONOMIC INDICATOR



Source: BofA Global Research, Bloomberg

Note: Measured from the lowest PMI reading in an economic recession

MULTIS RELATIVE PERFORMANCE VS S&P 500 FOLLOWING THE FIRST PEAK IN PMI READINGS




Source: BofA Global Research, Bloomberg

Note: Simple average of EMR, ETN, GE, HON, MMM, and PH share prices. Indexed to month of &&P500 trough

Thinking through the cycle for multis: valuation







Source: BofA Global Research, Bloomberg, Factset

Note: US recessions indicated by yellow periods. Simple average of EMR, ETN, GE, ON, MMM, and PH forward P/Es

Thinking through the cycle for multis: valuation



FORWARD P/E FOR MULTI-INDUSTRIAL STOCKS AND S&P 500 IN EARLY STAGES OF ECONOMIC RECOVERIES

	Multi-	S&P	Rel.																
	Industrials	500	P/E																
3/20	14.2x	16.3x	0.88x	2/09	9.5x	11.3x	0.84x	9/02	14.8x	14.7x	1.01x	10/90	8.9x	10.9x	0.82x	7/82	6.8x	12.6x	0.54x
4/20	18.3x	20.5x	0.89x	3/09	10.2x	12.6x	0.81x	10/02	15.9x	15.1x	1.06x	11/90	9.8x	11.7x	0.84x	8/82	8.0x	13.4x	0.59x
5/20	19.8x	21.6x	0.92x	4/09	14.2x	13.9x	1.02x	11/02	17.3x	16.0x	1.08x	12/90	10.5x	12.1x	0.87x	9/82	8.0x	12.6x	0.64x
6/20	19.7x	21.6x	0.91x	5/09	14.9x	14.4x	1.04x	12/02	17.0x	15.1x	1.13x	1/91	11.5x	12.6x	0.91x	10/82	9.9x	13.3x	0.75x
7/20	19.3x	21.8x	0.88x	6/09	15.0x	13.8x	1.09x	1/03	16.2x	14.8x	1.10x	2/91	11.9x	13.5x	0.88x	11/82	10.5x	13.5x	0.78x
8/20	20.7x	22.7x	0.91x	7/09	16.8x	14.5x	1.16x	2/03	15.7x	14.5x	1.09x	3/91	12.0x	13.9x	0.86x	12/82	10.5x	13.3x	0.79x
9/20	19.9x	21.4x	0.93x	8/09	18.1x	14.7x	1.24x	3/03	15.6x	14.5x	1.08x	4/91	12.3x	13.9x	0.89x	1/83	11.0x	13.4x	0.82x
10/20	19.9x	20.3x	0.98x	9/09	19.0x	14.9x	1.28x	4/03	16.9x	15.5x	1.09x	5/91	13.5x	14.5x	0.93x	2/83	11.5x	13.6x	0.85x
11/20	23.2x	21.9x	1.06x	10/09	17.2x	14.0x	1.23x	5/03	17.2x	16.2x	1.07x	6/91	13.2x	13.8x	0.96x	3/83	11.0x	12.7x	0.86x
12/20	24.1x	22.1x	1.09x	11/09	17.7x	14.4x	1.23x	6/03	17.5x	16.3x	1.07x	7/91	13.4x	14.3x	0.93x	4/83	11.4x	12.8x	0.89x
Δ	9.9x	5.9x	0.21x	Δ	8.2x	3.1x	0.39x	Δ	2.6x	1.7x	0.06x	Δ	4.5x	3.5x	0.12x	Δ	4.6x	0.2x	0.35x


Source: BofA Global Research, Bloomberg, Factset

Note: Multi-industrial is simple average of EMR, ETN, GE, ON, MMM, and PH forward P/Es



Estimating the impact of offshoring

- Method 1: manufacturing share of GDP
 - World Bank estimates manufacturing value-add was 17.5% of GDP in 1990 and 15.6% in 2019
 - We show hypothetical US manufacturing output <u>if</u> US had followed global trend
 - \$783bn difference, or \$27bn/year drag
 - Reflects more than just offshoring (e.g., exchange rates, US demand, etc.)
- Method 2: imported intermediary goods
 - In 1990, imported intermediate goods
 were 13.1% of US manufacturing output
 - By 2019, this had more than doubled to 26.5%
 - \$426bn difference, or \$15bn/year drag
 - Would not reflect final production moving to another country
- BofA view: outsourcing has been a meaningful drag which is set to slow
- 9 broadly and even reverse in select end markets



RISING INTERMEDIATE IMPORTS 3,500 3,000 Manufacturing output (constant 2012 US \$bn) (constant 2012 US \$bn) 1,000 Domestic inputs & value add 500 ■ Imported intermediate 1994 1998 2002 2006 2010 2014 2018 Source: BofA Global Research, Bureau of Labor Statistics




Where US manufacturing has been hardest hit


Technology hardware manufacturing is the main cause of declining US manufacturing since 2000 Printing, apparel, motor vehicles & parts, and textiles other areas of steep declines

(\$bn)	2020 YTD	2019	2018	2010	2000	1990	1980	1972
Fabricated Metal Products	232	248	245	204	232	147	135	126
Motor Vehicles and Parts	232	234	252	171	231	130	91	137
Machinery	219	231	236	209	232	160	176	161
Computers and Electronic Products	210	219	209	241	424	240	146	100
Aerospace/Misc Transportation Eqpt	157	183	180	164	131	133	104	82
Primary Metals	114	127	127	113	93	76	104	106
Miscellaneous Manufacturing	110	116	115	122	113	69	42	44
Nonmetallic Mineral Products	96	100	97	60	85	56	49	52
Electrical Equip/Appliances/Components		80	78	70	97	67	59	62
Wood Products	63	63	61	35	53	33	29	42
Furniture and Related Products	46	52	50	39	68	40	29	31
Durable Manufacturing	1,554	1,653	1,650	1,427	1,760	1,151	965	943
Chemicals	559	553	552	446	366	278	174	156
Food, Beverages, and Tobacco	483	496	481	426	431	290	177	178
Plastics and Rubber Products	149	151	152	111	140	85	51	56
Petroleum and Coal Products	120	139	149	138	74	43	54	30
Paper & Paper Products	101	102	104	99	121	97	64	60
Printing and Related Support Activities	48	54	55	60	99	74	42	38
Textiles and Product Mills	25	27	27	28	53	47	42	57
Apparel and Leather Goods	7	7	8	11	49	58	58	72
Nondurable Manufacturing	1,492	1,529	1,527	1,319	1,333	973	662	648
TOTAL MANUFACTURING	3,046	3,183	3,177	2,747	3.092	2,124	1,627	1,591



Where US manufacturing has been hardest hit






Source: BofA Global Research, Federal Reserve



Impact of manufacturing moving back west for Industrials

- We estimate that every \$10bn of manufacturing revenue brought back to the US generates ~\$3.8bn in PP&E spending (1/3 buildings, 2/3 equipment)
- Our calculation is based off the ratio of gross PP&E to revenue for industrial companies in the S&P 500
- If \$70bn of manufacturing revenue were re-shored, this would add 100bp to US capex growth over the next decade
 - vs. growing at a 2.3% CAGR over the last ten years



US industrials have steadily reduced diversification...




- We estimate that corporate actions by US publicly traded industrial firms have reduced diversification by 1.0% of market cap <u>annually</u> since 2000
- Examples in our coverage:
 - Emerson has divested \$12bn of revenue vs. \$18bn of revenue in 2019
 - Dover has divested 45% of its revenue since 2008
 - Trane Technologies has sold or spun-off \$25bn of assets since 2000





THE BENEFIT OF DIVERSIFICATION – AVERAGE REVENUE VOLATILITY (1987-2018)




Source: Bureau of Labor Statistics, BofA Global Research





LOWER ORGANIC REVENUE GROWTH VOLATILITY CORRELATED WITH HIGHER VALUATIONS




Source: BofA Global Research, Bloomberg

Oil & gas industry has not seen cost efficiency gains



Limited cost productivity

- Finding & lifting costs in 2019 were roughly flat with 2008 at \$35/bbl
- Technical advances in hydraulic fracturing, drilling technology geared towards <u>capacity</u> growth versus <u>cost</u> efficiency



Source: US Energy Information Administration, BofA Global Research Note: excludes proved reserve revisions

Limited labor productivity

- US oil & gas companies produced 46 barrels/employee/day in 1992 versus 42 in 2019
- Nearly 30-year stretch of stagnant labor productivity


O&G LABOR PRODUCTIVITY HAS BEEN STAGNANT





Source: US Energy Information Administration, Bureau of Labor Statistics, BofA Global Research Note: Payrolls of oil & gas extraction, support activities for oil & gas operations, and manufacture of oil operations

Oil & gas has under-invested in IP/software










software. Includes non-industry focused software (e.g., Microsoft Office)

Oil & gas industry automation market



Oil & gas automation revenue

- Tied to oil & gas capex cycles (61% R2)
- However far less volatile than overall oil
 & gas capex
- Aided by increasing mix of recurring revenue




Source: BofA Global Research

Note: Automation proxy is Emerson & Honeywell oil & gas automation revenue.

O&G automation market is OpEx-focused

- Software 32% of market mix of license and SaaS
- Services 28% of market mix of projectbased and recurring (MRO) services
- SaaS software and MRO services likely to see faster revenue growth

BREAKOUT OF O&G AUTOMATION MARKET



Source: US Energy Information Administration, Bureau of Labor Statistics, BofA Global Research Note: Payrolls of oil & gas extraction, support activities for oil & gas operations, and manufacture of oil operations

Oil & gas industry automation market




Oil & gas capex forecast

- Bottom-up capex estimates from BofA analysts
- 2021 capex is forecast to rebound
- Automation likely gains share within capex budgets

Multi-industrial coverage

- Emerson 26% of revenue tied to O&G automation
- Honeywell 7% of revenue tied to O&G automation (excludes UOP revenue)
- AspenTech ~40% of revenue from upstream & midstream customers

O&G CAPEX SET TO REBOUND IN 2021



Source: BofA Global Research

O&G REVENUE FOR SELECTED AUTOMATION & S/W FIRMS

(\$bn)	Upstream	Midstream	Downstream	Total	Market share
Emerson	2.4	1.3	1.1	4.8	17%
Honey w ell	0.6	0.7	1.2	2.5	9%
ABB	0.6	0.4	0.3	1.4	5%
Siemens	0.3	0.3	0.6	1.3	5%
Rockwell	0.5	0.1	0.1	0.7	2%
AspenTech	0.1	0.0	0.2	0.2	1%
Others	<u>7.0</u>	<u>4.1</u>	<u>5.5</u>	<u>16.6</u>	<u>60%</u>
Total market	11.5	7.0	9.0	27.5	100%

Source: BofA Global Research, company estimates

Note: Emerson, Honeywell, Rockwell, and AspenTech covered by Andrew Obin. Siemens and ABB


covered by Alexander Virgo.

Multi-industrials with non-residential construction exposure



- We believe upside to 2021 non-residential construction should benefit Buy-rated: ETN, ALLE,
 PH (indirect exposure through machinery), EMR, HON, and VRT
- Among our coverage, companies with the greatest non-residential building exposure are: ALLE,
 TT, and RXN. We classify Buy-rated VRT's exposure as data centers (100% of sales)

MULTI-INDUSTRIALS WITH EXPOSURE TO NON-RESIDENTIAL BUILDING CONSTRUCTION



Source: BofA Global Research, company filings

YTD non-residential construction starts are down 28% y/y




VALUE OF US CONSTRUCTION STARTS AS OF OCTOBER 2020

Hotel/Motel Retail/Shopping	Jan-Oct 2020 Construction Starts (\$bn) 8.8	% Change Jan-Oct 20 vs Jan-Oct 19 -53.0% -29.6%	% Change Oct 20 vs Oct 19 -78.9%
Parking Garage	1.6	-43.3%	-68.5%
Amusement	5.2	-20.1%	-25.2%
Private Office	17.7	-39.5%	-70.3%
Gov ernment Office	9.4	-4.7%	-35.0%
Laboratory	1.5	-21.4%	-8.6%
Warehouse	19.0	3.1%	2.7%
Miscellaneous Commercial*	6.2	-65.9%	-75.8%
TOTAL COMMERCIAL	79.4	-33.8%	-52.0%
INDUSTRIAL (Manufacturing)	16.1	-68.5%	-31.8%
Religious	1.2	-20.1%	12.2%
Hospital/Clinic	9.5	-44.3%	-59.4%
Nursing/Assisted Living	5.4	-35.8%	-31.6%
Library/Museum	3.4	-4.6%	-74.2%
Fire/Police/Courthouse/Prison	6.2	5.5%	-12.4%
Military	7.7	85.9%	2.3%
School/College	56.6	-14.4%	-27.2%
Miscellaneous Medical	5.8	-27.6%	-50.2%
INSTITUTIONAL	95.9	-16.4%	-34.7%
Miscellaneous Non-residential	4.5	-28.5%	-54.7%
NONRESIDENTIAL BUILDING	196.0	-33.0%	-42.6%
Airport	5.2	-20.8%	-55.6%
Road/Highw ay	54.5	-4.3%	-5.6%
Bridge	19.0	-28.9%	-50.4%
Dam/Marine	6.9	-3.3%	0.9%
Water/Sew age	27.0	4.0%	-6.1%
Miscellaneous Civil	18.4	-50.5%	-85.1%
HEAVY ENGINEERING (Civil)	130.9	-18.4%	-39.7%
TOTAL NONRESIDENTIAL	326.9	-27.8%	-41.5%

Non-residential spending tends to decline in recessions...








Source: BofA Global Research, US Census Bureau Note: Grey areas highlight periods of US recession Note: BofA Economics team forecasts used for 2020E and

2021E. Forecasts as of 12/04/20


...and lags residential construction by 1 to 2.5 years



Municipal bond issuances could tell a better story



- In 2019, issuances were +23% y/y. Municipal borrowings are also up YTD. Due to the long-cycle nature of construction, we view recent bond issuance trends as positive indicators for 2021 spending
- New money bonds are up 1% year-to-date. We note these moneys are used to fund new projects (versus refinancing)
- Education bond issuances are up 24% YTD. While healthcare bonds are down 12% YTD, issuances have substantially accelerated from trough levels in the spring



MUNICIPALS ISSUANCE SUMMARY, AS OF 12/04/20 MTD YTD


		MID			YID	
(\$mn)	4-Dec-20	4-Dec-19	YoY % Δ	4-Dec-20	4-Dec-19	YoY % Δ
Total	7,524	9,521	-21%	449,168	393,343	14%
New Money	5,494	6,636	-17%	250,372	247,944	1%
Total Refunding	2,030	2,885	-30%	198,796	145,399	37%
Transportation	2,774	2,997	-7%	58,260	62,943	-7%
Education	1,496	2,193	-32%	131,129	105,853	24%
Utilities	998	710	40%	49,849	42,798	16%
General Purpose	757	1,235	-39%	122,686	90,734	35%
Housing	746	632	18%	23,414	24,652	-5%
Dev elopment	492	563	-13%	12,149	10,089	20%
Healthcare	125	179	-30%	30,753	35,064	-12%
Electric Power	90	17	439%	10,119	10,295	-2%
Public Facilities	24	941	-97%	8,784	7,246	21%
Environmental Facilities	22	55	-60%	2,025	3,670	-45%

Source: BofA Municipals Research, Refinitiv

Bond issuances have been resilient this year




- Issuances from June through October all came ahead of BofA forecasts. November was an outlier this year, because of the federal election. Municipalities tend to avoid issuing bonds in volatile environments
- YTD, education bond issuances are above the 10-year average. General purpose, transportation
 and utilities issuances YTD are also trending above-average. Healthcare issuances are trending
 in line with its 10-year average
- As of mid-November, voters approved over \$38bn of bonds on ballots— more than three quarters of the \$45bn up for vote on Nov. 3




Source: BofA Municipals Research, Refinitiv. Note: Max, min, and average are YTD levels of each year for the past 10 years. 2020 YTD is as of December 4 2020.

REIT rent collections are recovering from April lows








Source: BofA REITs Global Research, company filings Office REITs include: AHH, ARE, BDN, BXP, CLI, CUZ, DEI, EQC, ERST, HIW, HPP, JBGS, KRC, OFC, OPI, PGRE, SLG, VNO, and WRE

Architecture billings index shows V-shaped recovery



Stocks mentioned



STOCKS MENTIONED

	Ticker	Rating	Price
3M	MMM	B-2-7	\$ 176.42
Allegion	ALLE	B-1-7	\$ 113.75
AMETEK Inc	AME	B-1-7	\$ 118.10
Aspen Technology, Inc.	AZPN	B-2-9	\$ 129.87
Colfax	CFX	C-1-9	\$ 36.57
Dov er	DOV	B-1-7	\$ 123.86
Eaton Corp.	ETN	B-1-7	\$ 116.08
Emerson	EMR	B-1-7	\$ 80.90
Flowserve	FLS	B-3-7	\$ 37.28
Fortiv e	FTV	B-1-7	\$ 69.83
General Electric	GE	B-1-7	\$ 10.81
Honey w ell	HON	B-1-7	\$ 210.04
ITT	ITT	B-2-7	\$ 77.47
John Bean Technologies	JBT	B-3-7	\$ 120.07
Mistras Group	MG	C-3-9	\$ 7.54
Montrose Environmental Group	MEG	C-1-9	\$ 31.70
Parker Hannifin	PH	B-1-7	\$ 272.00
Pentair	PNR	B-3-7	\$ 52.26
PTC, Inc.	PTC	B-1-9	\$ 118.39
Rexnord	RXN	B-2-7	\$ 37.41
Rockwell	ROK	B-1-7	\$ 247.95
Rush Enterprises	RUSHA	B-1-7	\$ 41.09
SPX Flow	FLOW	C-3-9	\$ 59.11
Trane Technologies	TT	B-3-7	\$ 141.06
Vertiv	VRT	B-1-9	\$ 19.19

Source: BofA Global Research, Bloomberg



3M Company (MMM)

We base our \$190 price objective on a 20.5x P/E on our 2021 estimates. Our 20.5x target multiple is at a discount to Industrial peers trading at 28x on 2020 estimates. 20.5x is also at a discount to high quality consumer goods peers trading on 2020E. A 2021E P/E multiple of 20.5x translates into 14x EV/EBITDA on our 2021 estimates. We believe valuation at a discount to peers is warranted given 3M's lower growth outlook, choppier execution, and PFAS liability risk.

Downside risks to our PO are: 1) the company's large global and emerging market exposure, 2) a need for greater investment could be a margin headwind, 3) slower-than-anticipated global economic recovery, and 4) greater-than-expected PFAS litigation impact.

Allegion (ALLE)

We base our \$141 price objective on a 19x EV/EBITDA of our 2022 estimates. Our 19x target multiple is at a premium to peers trading at 12x on 2021E, which we think is warranted given secular growth from electromechanical lock adoption, better-than-expected non-residential market heading into 2021, and strong residential backlog.

Downside risks to our PO are: 1) The cost takeout and restructuring plan may prove too ambitious, 2) acquisition integration may be a risk to execution, and 3) Emerging market slowdown could impact the company's growth, reliant on increased security demand from urbanization.

AMETEK Inc (AME)

We base our \$123 price objective on a 21x EV/EBITDA multiple of our 2021 estimates. Our target 21x multiple is in line with the peer average on 2020E, which we view as fair given Ametek's higher margins, balanced by a somewhat more cyclical portfolio.

Downside risks to our price objective are: 1) weaker industrial production trends, 2) slower pace of acquisitions, and 3) disruption in the ongoing relocation of labor to low-cost countries.

AspenTech (AZPN)

We arrive at our \$150 PO by applying a 24x EV/EBITDA multiple to our CY22E. This is in line with comps trading at 24x CY21E, which we think is supported by best-in-class EBITDA margins balanced by AZPN's greater exposure to oil & gas markets relative to peers. We view AZPN as appropriately valued at current levels, and see limited upside to valuation given our expectation for oil prices to remain below \$50 through 2021. On P/S, our PO translates to 13x our CY22 revenue forecast.

Downside risks to our PO: oil price volatility and oil prices below \$50, capex headwinds continues beyond 2021 and APM adoption rate disappoints.

Colfax Corporation (CFX)

We base our \$42 price objective on a 13x EV/EBITDA multiple of our 2021 estimates. Our target multiple is a discount to multi-industrial peers trading at 14x 2021E EBITDA and a discount to orthopedic stocks, which trade at 15x 2021E EBITDA. We argue a discount is warranted given above-peer leverage. Downside risks to our PO are: 1) global capex cycle deteriorating, particularly in emerging markets, 2) challenges improving the MedTech segment, and 3) greater competition.

Dover Corp (DOV)

We base our \$142 price objective on a 15x EV/EBITDA multiple of our 2022 estimates. Our target multiple is at a discount to multi-industrial peers trading at 17x 2021 estimates. We argue a discounted valuation is fair given the comp group multiple has moved up substantially and DOV's lower EBITDA margins.

Downside risks to our PO are: 1) slowing US industrial production, 2) not achieving expected returns from organic investments or acquisitions, and 3) slower-than-expected margin improvement.



Eaton Corp PLC (ETN)

We base our \$135 price objective on a 16x EV/EBITDA multiple of our 2021 estimates. Our target multiple is at a discount to peers, which trade at 17.5x 2020 estimates. We argue a discount is warranted given Eaton's lower EBITDA margins and improving, but more cyclical, portfolio mix.

Downside risks to our PO are: 1) a worse-than-expected global industrial recession, particularly in commercial construction, 2) a more active M&A is inherently risky as it relies on the availability of accretive synergistic targets and the company's ability to integrate, and 3) the trajectory of the recovery in automotive and aerospace end markets.

Emerson Electric Co (EMR)

We base our \$95 price objective on a 16x EV/EBITDA multiple of our 2021 estimates. Our target multiple is a discount to multi-industrial peers trading at around 19x 2020 estimates. We argue a discount is warranted, given above-peer oil & gas end market exposure.

Downside risks to our PO are: 1) deterioration in energy capex outlook or oil price correction 2) emerging market slowdown could impact the company's growth, and 3) worse-than-expected trends in global HVAC markets.

Flowserve (FLS)

We base our \$28 price objective on an 8x EV/EBITDA multiple on our 2021 estimates. An 8x multiple puts the company at a discount to the 14.5x peer average multiple on 2020. We think the discount is warranted given substantial exposure to oil & gas.

Upside risks to our PO are: 1) Recovery in 2020 oil & gas capital spending, and 2) Better than anticipated global industrial production growth. Downside risks: 1) a reduction in capital spending in the key end-markets, specifically oil & gas 2) Greater consolidation in the flow control market increases competition and reduces prices across the industry, and 3) weaker than anticipated global industrial production.

Fortive Corporation (FTV)

We base our \$72 price objective on a 23x EV/EBITDA multiple of our 2021 EBITDA. Our target multiple is in line with the peer average of 23x on 2020. We argue an in line multiple is warranted given FTV's above-average software mix (approximately 15% of revenue), offset by below-peer margins

Downside risks to our PO are: 1) Weaker-than-expected capex cycle, 2) Ability to redeploy cash into accretive acquisitions, 3) Further strengthening of US dollar.

General Electric Company (GE)

We base our \$13 price objective on a 13x EV/EBITDA multiple of our 2022 estimates. Our target multiple is a discount to the 14x peer average on 2021 estimates. We apply the 13x multiple to our 2022 estimates to yield our 12-month forward price objective of \$13. We argue a discount is appropriate, given higher leverage and lower EBITDA margins.

Downside risks to our PO are: 1) near-term end market pressures in Aviation, 2) Execution issues within Power, and 3) Larger-than-expected capital requirements at GE Capital.

Honeywell International Inc. (HON)

We base our \$240 price objective on 20x 20201E EV/EBITDA. Our target multiple is in line with the 20x peer average on 2020E. We argue an in line multiple is warranted given a more defensive portfolio yielding resilient margins and above average EPS growth balance by HON's exposure to challenged aerospace and oil & gas markets. HON also has some of the best balance sheet optionality in our coverage.

Downside risks to our price objective are: 1) Acquisitions, specifically that Honeywell overpays for deals in the pursuit of diversifying and expanding into new, faster-growing adjacent markets, 2) Unforeseen future sales deceleration due to economic pressures (e.g., slowing global flying hours, oil price volatility and muted O&G capex outlook), and 3) execution around ongoing simplification efforts.



ITT Inc. (ITT)

We base our \$75 price objective on a 12x EV/EBITDA multiple of our 2021 estimates. Our 12x target multiple is at a discount to the peer group trading at 14x on 2020E. We think the discounted valuation is warranted given significant cyclical end market exposure and asbestos liability risks.

Downside risks to our PO are: 1) ITT may overpay for deals in the pursuit of diversifying and expanding its product portfolio, 2) Lower capex spending in the auto, oil & gas, power gen, and other key end markets, 3) Uncertainties of asbestos litigation could be an overhang on the cash flow, 4) Greater consolidation in the flow control market may increase competition and reduce prices across the industry.

John Bean Technologies (JBT)

We base our \$65 price objective on a 10x EV/EBITDA multiple of our 2021 estimates. Our 10x target multiple is below the peer average trading on 2020E EBITDA. We argue a discounted valuation is warranted given JBT's recently slower organic growth, below-peer EBITDA margins, and below-peer cash conversion.

Upside risks to our PO are: 1) better than expected execution on restructuring/facility consolidation, 2) lower input cost inflation, and 3) faster pace of accretive M&A. Downside risks to our PO are: 1) valuation already implies future M&A, 2) ability to source accretive acquisitions, 3) execution risk in restructuring/facility consolidation, 4) input cost inflation, and 5) rising low-cost competition.

Mistras Group (MG)

We base our \$4.50 price objective on 5x EV/EBITDA multiple of our 2021 estimate. This is a discount to the average for Testing, Inspection and Certification peers at 13x on consensus 2021 estimates, which we think is appropriate given below-average EBITDA margin, elevated leverage and higher exposure to the oil & gas end market.

Upside risks to our PO are: 1) upside from further consolidation in the sector, and 2) ability to diversify into new markets and value-added services. Downside risks to our PO are: 1) the inability to source and integrate acquisitions, 2) historical lumpiness in growth and execution, 3) greater pricing pressure.

Montrose Environmental Group, Inc. (MEG)

We base our \$40 price objective on a 17.5x EV/EBITDA of our 2022 estimates. This is at a premium to the peer group average trading at 14.5x on 2020E. We believe the premium is warranted given secular growth trends from US environmental regulations, high growth driven by acquisitions and organic revenue, and a less cyclical revenue profile compared to other environmental services peers.

Downside risks to our PO are: 1) elevated financial leverage, 2) inability to source or integrate deals, and 3) poor execution tied to ERP rollout and initiation of European operations.

Parker Hannifin Corporation (PH)

We base our \$300 price objective on a 16.5x EV/EBITDA multiple applied to our CY21 estimate. Our 16.5x target multiple is in line with the multi-industrial peer average of around 16.5x on 2020E, but a premium to the 13x average for industrial suppliers. We argue this is warranted given in line EBITDA margins to multi-industrial peers, strong FCF conversion, and less cyclical earnings profile compared to prior downturns.

Downside risks are: 1) slowdown in Global Industrial production, 2) execution on corporate restructuring programs, and 3) the ability to offset material inflation through pricing.

Pentair plc (PNR)

We base our \$58 price objective on a 17x EV/EBITDA multiple of our 2021 estimates. This is below the peer group trading at 17.5x on 2020 estimates. We think the below-peer group valuation is fair given inconsistent organic revenue growth and below-peer earnings growth longer-term

Downside risks are: 1) weaker-than-expected revenue growth in end markets ex-pools 2) supply chain constraints limiting incremental margins for pools 3) weaker spending growth in Industrial and Resi/Commercial markets.



PTC Inc. (PTC)

Our PO of \$135 is based on 25.5x CY22E EV/EBITDA. This is in line to industrial software peers at 25.5x on CY21E, which we think is warranted given premium revenue growth and strong FCF trajectory, balanced by average EBITDA margins. We think the company's improving FCF warrants a multiple in line with comps. Our price objective translates into a 10x EV/Sales multiple on our CY22E, which is at a discount to peers at 11.5x.

Downside risks to our PO: Macro worsens, sticky product and significant competition in core PLM market limits market share gains, declines in discrete manufacturing activity, IoT and Augmented Reality new bookings slow down to below market growth, elevated leverage post OnShape and Arena acquisitions, acquisition integration risks.

Rexnord Corporation (RXN)

We base our \$40 price objective on a 12.5x EV/EBITDA of our CY 2021 estimate. This is below the peer group average of 16x EV/EBITDA on 2020 estimates. We argue discounted valuation is warranted due exposure to commercial aerospace as well as more traditional short-cycle end markets.

Downside risks are: 1) a slower than expected recovery in the company's key end markets, 2) disappointing operating leverage related to weaker than expected execution, 3) inability to source deals.

Rockwell (ROK)

We base our \$295 price objective on a 20x EV/EBITDA multiple of our CY22 estimate. Our target multiple is a premium to the 15x peer average on 2021E. We argue a premium is warranted given higher returns and higher margins of ROK versus peers.

Upside risks are: 1) better global industrial production, 2) improving global capex trends, 3) potentially accretive acquisitions. Downside risks are: 1) weaker global industrial production, 2) delays in global capex, 3) greater competition, and 4) unfavorable product mix.

Rush (RUSHA)

We base our \$51 price objective on a 21x P/E multiple of our 2021 EPS estimate. Our target multiple is a discount to the 22x average of industrial distributor peers on 2020 estimates. We argue a discount is warranted given expected 2020 trough earnings for peers.

Upside risks are: 1) improving mix of service-related revenue, 2) accretive use of free cash flow in either share repurchases or acquisitions, 3) an improvement in US truck market. Downside risks are: 1) Rush's relationship with PACCAR given the majority of revenue comes from the sale of PACCAR products, namely Peterbilt trucks and parts. 2) PACCAR has ultimate veto power on Rush's growth plans by virtue of having a right of first refusal on the purchase of additional Peterbilt dealerships. PACCAR may terminate Rush's dealership agreements upon change of control of the company from the Rush family or if the Rush family's aggregate voting power falls below 30%. 3) The heavy truck market is a highly cyclical business that can be affected by fuel prices, interest rate fluctuations, economic recessions and customer business cycles.



SPX Flow Inc. (FLOW)

We base our \$33 price objective on a 7.5x EV/EBITDA multiple on our 2021 estimates. Our target multiple is at a discount to the peer group average trading at 12.0x on 2020 estimates. We argue that a discount is warranted given weaker revenue and earnings quality versus peers.

Upside risks to our PO are: 1) restructuring benefits help offset pricing pressure and volume declines, 2) Food & Beverage margin expansion story sustainable through the cycle, and 3) FLOW valuation elevated due to potential for consolidation in flow control sector. Downside risks to our PO are: 1) Lower capex in the oil & gas, chemicals, industrials and other key end markets, 2) greater consolidation in the flow control market may increase competition and reduce prices across the industry, and 3) weaker than anticipated global industrial production growth.

Trane Technologies PLC (TT)

We base our \$156 price objective on 15.5x EV/EBITDA multiple of our 2022 estimates. Our 15.5x target multiple is in line with the peer group average trading on 2021 estimates. We think the in line valuation is warranted given strong ESG factor and heavy investment in product innovation, but limited positive earnings revision.

Downside risks to our PO are: 1) a slower-than-expected economic recovery or an outright Industrial recession, translating into weaker nonresidential construction activity, and 2) lower-than-expected productivity improvement and cost synergies.

Vertiv (VRT)

We base our \$23 price objective on a 15x EV/EBITDA multiple of our 2021 estimates. This is at a discount to the 16x peer average on 2020E. We argue a discount is warranted given lower margins and higher financial leverage versus peers.

Downside risks to our price objective are: 1) declines in company-owned data centers, 2) inability to execute on announced cost savings plans, 3) pricing deterioration due to competition, and 4) disruptions due to ERP rollout.

Analyst Certification



I, Andrew Obin, hereby certify that the views expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or view expressed in this research report.

Special Disclosures



BofA Securities is currently acting as Adviser to The Consortium (Partners Group, InfraRed Capital Partners, DEME Concessions, GE Energy Financial Services and ADEME) in connection with its proposed sale of Merkur Offshore to APG and the Renewables Infrastructure Group ("TRIG"), which was announced on December 10, 2019.

Important Disclosures



Equity Investment Rating Distribution: Electric	al Equipment Group (as of 30 Sep 2020)			
Coverage Universe	Count	Percent	Inv. Banking Relationships*	Count	Percent
Buy	17	68.00%	Buy	12	70.59%
Hold	3	12.00%	Hold	2	66.67%
Sell	5	20.00%	Sell	1	20.00%
Equity Investment Rating Distribution: Industr	ials/Multi-Industry Group (as of 30 Sep	2020)			
Coverage Universe	Count	Percent	Inv. Banking Relationships*	Count	Percent
Buy	47	55.95%	Buy	28	59.57%
Hold	17	20.24%	Hold	14	82.35%
Sell	20	23.81%	Sell	9	45.00%
Equity Investment Rating Distribution: Machin	ery/Diversified Manufacturing Group (as of 30 Sep 2020)			
Coverage Universe	Count	Percent	Inv. Banking Relationships*	Count	Percent
Buy	29	46.03%	Buy	14	48.28%
Hold	15	23.81%	Hold	9	60.00%
Sell	19	30.16%	Sell	7	36.84%
Equity Investment Rating Distribution: Techno	ology Group (as of 30 Sep 2020)				
Coverage Universe	Count	Percent	Inv. Banking Relationships*	Count	Percent
Buy	172	60.99%	Buy	115	66.86%
Hold	54	19.15%	Hold	35	64.81%
Sell	56	19.86%	Sell	24	42.86%

Important Disclosures



Equity Investment Rating Distribution: Global Group (as of 30 Sep 2020)

Coverage Universe	Count	Percent	Inv. Banking Relationships*	Count	Percent
Buy	1749	54.79%	Buy	1114	63.69%
Hold	677	21.21%	Hold	415	61.30%
Sell	766	24.00%	Sell	386	50.39%

^{*} Issuers that were investment banking clients of BofA Securities or one of its affiliates within the past 12 months. For purposes of this Investment Rating Distribution, the coverage universe includes only stocks. A stock rated Neutral is included as a Hold, and a stock rated Underperform is included as a Sell.

FUNDAMENTAL EQUITY OPINION KEY: Opinions include a Volatility Risk Rating, an Investment Rating and an Income Rating. VOLATILITY RISK RATINGS, indicators of potential price fluctuation, are: A - Low, B - Medium and C - High. INVESTMENT RATINGS reflect the analyst's assessment of a stock's: (i) absolute total return potential and (ii) attractiveness for investment relative to other stocks within its Coverage Cluster (defined below). There are three investment ratings: 1 - Buy stocks are expected to have a total return of at least 10% and are the most attractive stocks in the coverage cluster; 2 - Neutral stocks are expected to remain flat or increase in value and are less attractive than Buy rated stocks and 3 - Underperform stocks are the least attractive stocks in a coverage cluster. Analysts assign investment ratings considering, among other things, the 0-12 month total return expectation for a stock and the firm's guidelines for ratings dispersions (shown in the table below). The current price objective for a stock should be referenced to better understand the total return expectation (depreciation).

Investment rating	Total return expectation (within 12-month period of date of initial rating)	Ratings dispersion guidelines for coverage cluster*
Buy	≥ 10%	≤ 70%
Neutral	≥ 0%	≤ 30%
Underperform	N/A	≥ 20%

^{*} Ratings dispersions may vary from time to time where BofA Global Research believes it better reflects the investment prospects of stocks in a Coverage Cluster.

INCOME RATINGS, indicators of potential cash dividends, are: 7 - same/higher (dividend considered to be secure), 8 - same/lower (dividend not considered to be secure) and 9 - pays no cash dividends. Coverage Cluster is comprised of stocks covered by a single analyst or two or more analysts sharing a common industry, sector, region or other classification(s). A stock's coverage cluster is included in the most recent BofA Global Research report referencing the stock.

Important Disclosures



Price charts for the securities referenced in this research report are available at https://pricecharts.baml.com, or call 1-800-MERRILL to have them mailed.

BofAS or one of its affiliates acts as a market maker for the equity securities recommended in the report: 3M, Allegion, AMETEK, AspenTech, Colfax, Dover Corp, Eaton Corp PLC, Emerson, Flowserve, Fortive, General Electric, Honeywell, ITT Inc., John Bean Tech, Mistras Group, Montrose, Parker Hannifin, Pentair plc, PTC, Rexnord, Rockwell, Rush, SPX Flow, Trane Technologies, Vertiv.

BofAS or an affiliate was a manager of a public offering of securities of this issuer within the last 12 months: 3M, Emerson, Flowserve, General Electric Co, Honeywell, Montrose, PTC, Vertiv.

The issuer is or was, within the last 12 months, an investment banking client of BofAS and/or one or more of its affiliates: 3M, Allegion, Dover Corp, Eaton Corp PLC, Emerson, Flowserve, Fortive Corporation, General Electric Co, Honeywell, John Bean Tech, Mistras Group, Montrose, Parker Hannifin, Pentair plc, PTC, Rockwell, SPX Flow Inc., Trane Technologies, Vertiv.

BofAS or an affiliate has received compensation from the issuer for non-investment banking services or products within the past 12 months: 3M, Allegion, AMETEK Inc, Colfax, Dover Corp, Eaton Corp PLC, Emerson, Flowserve, Fortive Corporation, General Electric Co, Honeywell, John Bean Tech, Mistras Group, Montrose, Parker Hannifin, Pentair plc, PTC, Rexnord, Rockwell, Rush, SPX Flow Inc., Trane Technologies, Vertiv.

The issuer is or was, within the last 12 months, a non-securities business client of BofAS and/or one or more of its affiliates: 3M, Allegion, AMETEK Inc, Colfax, Dover Corp, Eaton Corp PLC, Emerson, Flowserve, Fortive Corporation, General Electric Co, Honeywell, John Bean Tech, Mistras Group, Montrose, Parker Hannifin, Pentair plc, PTC, Rexnord, Rockwell, Rush, SPX Flow Inc., Trane Technologies, Vertiv.

An officer, director or employee of BofAS or one of its affiliates is an officer or director of this issuer: Trane Technologies.

BofAS or an affiliate has received compensation for investment banking services from this issuer within the past 12 months: 3M, Allegion, Dover Corp, Eaton Corp PLC, Emerson, Flowserve, Fortive Corporation, General Electric Co, Honeywell, John Bean Tech, Mistras Group, Montrose, Parker Hannifin, Pentair plc, PTC, Rockwell, Trane Technologies, Vertiv.

BofAS or an affiliate expects to receive or intends to seek compensation for investment banking services from this issuer or an affiliate of the issuer within the next three months: 3M, Dover Corp, Eaton Corp PLC, Emerson, Flowserve, General Electric Co, Honeywell, Mistras Group, Montrose, Pentair plc, Rockwell, SPX Flow Inc., Trane Technologies, Vertiv.

BofAS together with its affiliates beneficially owns one percent or more of the common stock of this issuer. If this report was issued on or after the 9th day of the month, it reflects the ownership position on the last day of the previous month. Reports issued before the 9th day of a month reflect the ownership position at the end of the second month preceding the date of the report: 3M, Dover Corp, Eaton Corp PLC, Emerson, Fortive Corporation, Honeywell, Parker Hannifin, Rockwell, Trane Technologies.

BofAS or one of its affiliates is willing to sell to, or buy from, clients the common equity of the issuer on a principal basis: 3M, Allegion, AMETEK, AspenTech, Colfax, Dover Corp, Eaton Corp PLC, Emerson, Flowserve, Fortive, General Electric, Honeywell, ITT Inc., John Bean Tech, Mistras Group, Montrose, Parker Hannifin, Pentair plc, PTC, Rexnord, Rockwell, Rush, SPX Flow, Trane Technologies, Vertiv.

The issuer is or was, within the last 12 months, a securities business client (non-investment banking) of BofAS and/or one or more of its affiliates: 3M, Allegion, AMETEK Inc, Colfax, Dover Corp, Eaton Corp PLC, Emerson, Flowserve, Fortive Corporation, General Electric Co, Honeywell, John Bean Tech, Mistras Group, Montrose, Parker Hannifin, Pentair plc, PTC, Rockwell, Rush, SPX Flow Inc., Trane Technologies, Vertiv.

BofA Global Research personnel (including the analyst(s) responsible for this report) receive compensation based upon, among other factors, the overall profitability of Bank of America Corporation, including profits derived from investment banking. The analyst(s) responsible for this report may also receive compensation based upon, among other factors, the overall profitability of the Bank's sales and trading businesses relating to the class of securities or financial instruments for which such analyst is responsible.



Prices are indicative and for information purposes only. Except as otherwise stated in the report, for the purpose of any recommendation in relation to: (i) an equity security, the price referenced is the publicly traded price of the security as of close of business on the day prior to the date of the report or, if the report is published during intraday trading, the price referenced is indicative of the traded price as of the date and time of the report; or (ii) a debt security (including equity preferred and CDS), prices are indicative as of the date and time of the report and are from various sources including BofA Securities trading desks.

Officers of BofAS or one or more of its affiliates (other than research analysts) may have a financial interest in securities of the issuer(s) or in related investments.

BofA Global Research policies relating to conflicts of interest are described at https://rsch.baml.com/coi "BofA Securities" includes BofA Securities, Inc. ("BofAS") and its affiliates. Investors should contact their BofA Securities representative or Merrill Global Wealth Management financial advisor if they have questions concerning this report or concerning the appropriateness of any investment idea described herein for such investor. "BofA Securities" is a global brand for BofA Global Research.

Information relating to Non-US affiliates of BofA Securities and Distribution of Affiliate Research Reports:

BofAS and/or Merrill Lynch, Pierce, Fenner & Smith ("MLPF&S") may in the future distribute, information of the following non-US affiliates in the US (short name: legal name, regulator): Merrill Lynch (South Africa): Merrill Lynch South Africa (Pty) Ltd., regulated by The Financial Service Board; MLI (UK): Merrill Lynch International, regulated by the Financial Conduct Authority (FCA) and the Prudential Regulation Authority (PRA); BofASE (France): BofA Securities Europe SA is authorized by the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and regulated by the ACPR and the Autorité des Marchés Financiers (AMF); BofA Europe (Milan): Bank of America Europe Designated Activity Company, Milan Branch, regulated by the Bank of Italy, the European Central Bank (ECB) and the Central Bank of Ireland (CBI); BofA Europe (Frankfurt): Bank of America Europe Designated Activity Company, Frankfurt Branch regulated by BaFin, the ECB and the CBI; Merrill Lynch (Australia): Merrill Lynch (Australia) Limited, regulated by the Australian Securities and Investments Commission; Merrill Lynch (Hong Kong); Merrill Lynch (Asia Pacific) Limited, regulated by the Hong Kong Securities and Futures Commission (HKSFC); Merrill Lynch (Singapore): Merrill Lynch (Singapore) Pte Ltd, regulated by the Monetary Authority of Singapore (MAS); Merrill Lynch (Canada): Merrill Lynch Canada Inc, regulated by the Investment Industry Regulatory Organization of Canada; Merrill Lynch (Mexico): Merrill Lynch Mexico, SA de CV, Casa de Bolsa, regulated by the Comisión Nacional Bancaria y de Valores; Merrill Lynch (Argentina): Merrill Lynch Argentina SA, regulated by Comisión Nacional de Valores; BofAS Japan: BofA Securities Japan Co., Ltd., regulated by the Financial Services Agency; Merrill Lynch (Seoul): Merrill Lynch International, LLC Seoul Branch, regulated by the Financial Supervisory Service; Merrill Lynch (Taiwan): Merrill Lynch Securities (Taiwan) Ltd., regulated by the Securities and Futures Bureau; BofAS India; BofA Securities India Limited, regulated by the Securities and Exchange Board of India (SEBI); Merrill Lynch (Indonesia); PT Merrill Lynch Sekuritas Indonesia, regulated by Otoritas Jasa Keuangan (OJK); Merrill Lynch (Israel): Merrill Lynch Israel Limited, regulated by Israel Securities Authority; Merrill Lynch (Russia): OOO Merrill Lynch Securities, Moscow, regulated by the Central Bank of the Russian Federation; Merrill Lynch (DIFC): Merrill Lynch International (DIFC Branch), regulated by the Dubai Financial Services Authority (DFSA); Merrill Lynch (Spain): Merrill Lynch (Spain): Merrill Lynch (Brazil): Merrill Lynch (Brazil): Merrill Lynch (Brazil): Merrill Lynch (Spain): M Títulos e Valores Mobiliários, regulated by Comissão de Valores Mobiliários; Merrill Lynch KSA Company; Merrill Lynch Kingdom of Saudi Arabia Company, regulated by the Capital Market Authority.

This information: has been approved for publication and is distributed in the United Kingdom (UK) to professional clients and eligible counterparties (as each is defined in the rules of the FCA and the PRA) by MLI (UK), which is authorized by the PRA and regulated by the FCA and the PRA - details about the extent of our regulation by the FCA and PRA are available from us on request; has been approved for publication and is distributed in the European Economic Area (EEA) by BofASE (France), which is authorized by the ACPR and regulated by the ACPR and the AMF; has been considered and distributed in Japan by BofAS Japan, a registered securities dealer under the Financial Instruments and Exchange Act in Japan, or its permitted affiliates; is issued and distributed in Taiwan by Merrill Lynch (Hong Kong) which is regulated by HKSFC; is issued and distributed in Taiwan by Merrill Lynch (Taiwan); is issued and distributed in India by BofAS India; and is issued and distributed in Singapore to institutional investors and/or accredited investors (each as defined under the Financial Advisers Regulations) by Merrill Lynch (Singapore) (Company Registration No 198602883D). Merrill Lynch (Singapore) is regulated by MAS. Merrill Lynch Equities (Australia) Limited (ABN 65 006 276 795), AFS License 235132 (MLEA) distributes this information in Australia only to 'Wholesale' clients as defined by s.761G of the Corporations Act 2001. With the exception of Bank of America N.A., Australia Branch, neither MLEA nor any of its affiliates involved in preparing this information is an Authorised Deposit-Taking Institution under the Banking Act 1959 nor regulated by the Australian Prudential Regulation Authority. No approval is required for publication or distribution of this information in Brazil and its local distribution is by Merrill Lynch (Brazil) in accordance with applicable regulations. Merrill Lynch (DIFC) is authorized and regulated by the DFSA. Information prepared and issued by Merrill Lynch (DIFC) is done so in accordance with



This information has been prepared and issued by BofAS and/or one or more of its non-US affiliates. The author(s) of this information may not be licensed to carry on regulated activities in your jurisdiction and, if not licensed, do not hold themselves out as being able to do so. BofAS and/or MLPF&S is the distributor of this information in the US and accepts full responsibility for information distributed to BofAS and/or MLPF&S clients in the US by its non-US affiliates. Any US person receiving this information and wishing to effect any transaction in any security discussed herein should do so through BofAS and/or MLPF&S and not such foreign affiliates. Hong Kong recipients of this information should contact Merrill Lynch (Asia Pacific) Limited in respect of any matters relating to dealing in securities or provision of specific advice on securities or any other matters arising from, or in connection with, this information. Singapore recipients of this information should contact Merrill Lynch (Singapore) Pte Ltd in respect of any matters arising from, or in connection with, this information.

General Investment Related Disclosures:

Taiwan Readers: Neither the information nor any opinion expressed herein constitutes an offer or a solicitation of an offer to transact in any securities or other financial instrument. No part of this report may be used or reproduced or quoted in any manner whatsoever in Taiwan by the press or any other person without the express written consent of BofA Securities.

This document provides general information only, and has been prepared for, and is intended for general distribution to, BofA Securities clients. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other financial instrument or any derivative related to such securities or instruments (e.g., options, futures, warrants, and contracts for differences). This document is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of, and is not directed to, any specific person(s). This document and its content do not constitute, and should not be considered to constitute, investment advice for purposes of ERISA, the US tax code, the Investment Advisers Act or otherwise. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Any decision to purchase or subscribe for securities in any offering must be based solely on existing public information on such security or the information in the prospectus or other offering document issued in connection with such offering, and not on this document.

Securities and other financial instruments referred to herein, or recommended, offered or sold by BofA Securities, are not insured by the Federal Deposit Insurance Corporation and are not deposits or other obligations of any insured depository institution (including, Bank of America, N.A.). Investments in general and, derivatives, in particular, involve numerous risks, including, among others, market risk, counterparty default risk and liquidity risk. No security, financial instrument or derivative is suitable for all investors. In some cases, securities and other financial instruments may be difficult to value or sell and reliable information about the value or risks related to the security or financial instrument may be difficult to obtain. Investors should note that income from such securities and other financial instruments, if any, may fluctuate and that price or value of such securities and instruments may rise or fall and, in some cases, investors may lose their entire principal investment. Past performance is not necessarily a guide to future performance. Levels and basis for taxation may change.

This report may contain a short-term trading idea or recommendation, which highlights a specific near-term catalyst or event impacting the issuer or the market that is anticipated to have a short-term price impact on the equity securities of the issuer. Short-term trading ideas and recommendations are different from and do not affect a stock's fundamental equity rating, which reflects both a longer term total return expectation and attractiveness for investment relative to other stocks within its Coverage Cluster. Short-term trading ideas and recommendations may be more or less positive than a stock's fundamental equity rating.

BofA Securities is aware that the implementation of the ideas expressed in this report may depend upon an investor's ability to "short" securities or other financial instruments and that such action may be limited by regulations prohibiting or restricting "shortselling" in many jurisdictions. Investors are urged to seek advice regarding the applicability of such regulations prior to executing any short idea contained in this report.

Foreign currency rates of exchange may adversely affect the value, price or income of any security or financial instrument mentioned herein. Investors in such securities and instruments, including ADRs, effectively assume currency risk.

UK Readers: The protections provided by the U.K. regulatory regime, including the Financial Services Scheme, do not apply in general to business coordinated by BofA Securities entities located outside of the United Kingdom.



BofAS or one of its affiliates is a regular issuer of traded financial instruments linked to securities that may have been recommended in this report. BofAS or one of its affiliates may, at any time, hold a trading position (long or short) in the securities and financial instruments discussed in this report.

BofA Securities, through business units other than BofA Global Research, may have issued and may in the future issue trading ideas or recommendations that are inconsistent with, and reach different conclusions from, the information presented herein. Such ideas or recommendations may reflect different time frames, assumptions, views and analytical methods of the persons who prepared them, and BofA Securities is under no obligation to ensure that such other trading ideas or recommendations are brought to the attention of any recipient of this information.

In the event that the recipient received this information pursuant to a contract between the recipient and BofAS for the provision of research services for a separate fee, and in connection therewith BofAS may be deemed to be acting as an investment adviser, such status relates, if at all, solely to the person with whom BofAS has contracted directly and does not extend beyond the delivery of this report (unless otherwise agreed specifically in writing by BofAS if such recipient uses the services of BofAS in connection with the sale or purchase of a security referred to herein, BofAS may act as principal for its own account or as agent for another person. BofAS is and continues to act solely as a broker-dealer in connection with the execution of any transactions, including transactions in any securities referred to herein.

Copyright and General Information:

Copyright 2020 Bank of America Corporation. All rights reserved. iQprofile^{5M}, iQmethod^{5M} are service marks of Bank of America Corporation. iQdatabase[®] is a registered service mark of Bank of America Corporation. This information is prepared for the use of BofA Securities clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of BofA Securities. BofA Global Research information is distributed simultaneously to internal and client websites and other portals by BofA Securities and is not publicly-available material. Any unauthorized use or disclosure is prohibited. Receipt and review of this information constitutes your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained herein (including any investment recommendations, estimates or price targets) without first obtaining express permission from an authorized officer of BofA Securities.

Materials prepared by BofA Global Research personnel are based on public information. Facts and views presented in this material have not been reviewed by, and may not reflect information known to, professionals in other business areas of BofA Securities, including investment banking personnel. BofA Securities has established information barriers between BofA Global Research and certain business groups. As a result, BofA Securities does not disclose certain client relationships with, or compensation received from, such issuers. To the extent this material discusses any legal proceeding or issues, it has not been prepared as nor is it intended to express any legal conclusion, opinion or advice. Investors should consult their own legal advisers as to issues of law relating to the subject matter of this material. BofA Global Research personnel's knowledge of legal proceedings in which any BofA Securities entity and/or its directors, officers and employees may be plaintiffs, defendants, co-defendants or co-plaintiffs with or involving issuers mentioned in this material is based on public information. Facts and views presented in this material that relate to any such proceedings have not been reviewed by, discussed with, and may not reflect information known to, professionals in other business areas of BofA Securities in connection with the legal proceedings or matters relevant to such proceedings.

This information has been prepared independently of any issuer of securities mentioned herein and not in connection with any proposed offering of securities or as agent of any issuer of any securities. None of BofAS any of its affiliates or their research analysts has any authority whatsoever to make any representation or warranty on behalf of the issuer(s). BofA Global Research policy prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer prior to the publication of a research report containing such rating, recommendation or investment thesis.



Any information relating to the tax status of financial instruments discussed herein is not intended to provide tax advice or to be used by anyone to provide tax advice. Investors are urged to seek tax advice based on their particular circumstances from an independent tax professional.

The information herein (other than disclosure information relating to BofA Securities and its affiliates) was obtained from various sources and we do not guarantee its accuracy. This information may contain links to third-party websites. BofA Securities is not responsible for the content of any third-party website or any linked content contained in a third-party website. Content contained on such third-party websites is not part of this information and is not incorporated by reference. The inclusion of a link does not imply any endorsement by or any affiliation with BofA Securities.

Access to any third-party website is at your own risk, and you should always review the terms and privacy policies at third-party websites before submitting any personal information to them. BofA Securities is not responsible for such terms and privacy policies and expressly disclaims any liability for them.

All opinions, projections and estimates constitute the judgment of the author as of the date of publication and are subject to change without notice. Prices also are subject to change without notice. BofA Securities is under no obligation to update this information and BofA Securities ability to publish information on the subject issuer(s) in the future is subject to applicable quiet periods. You should therefore assume that BofA Securities will not update any fact, circumstance or opinion contained herein.

Subject to the quiet period applicable under laws of the various jurisdictions in which we distribute research reports and other legal and BofA Securities policy-related restrictions on the publication of research reports, fundamental equity reports are produced on a regular basis as necessary to keep the investment recommendation current.

Certain outstanding reports or investment opinions relating to securities, financial instruments and/or issuers may no longer be current. Always refer to the most recent research report relating to an issuer prior to making an investment decision.

In some cases, an issuer may be classified as Restricted or may be Under Review or Extended Review. In each case, investors should consider any investment opinion relating to such issuer (or its security and/or financial instruments) to be suspended or withdrawn and should not rely on the analyses and investment opinion(s) pertaining to such issuer (or its securities and/or financial instruments) nor should the analyses or opinion(s) be considered a solicitation of any kind. Sales persons and financial advisors affiliated with BofAS or any of its affiliates may not solicit purchases of securities or financial instruments that are Restricted or Under Review and may only solicit securities under Extended Review in accordance with firm policies.

Neither BofA Securities nor any officer or employee of BofA Securities accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this information.